M-TCR is developing cell therapies that utilize T cells to target the MR1 molecule, which recognizes metabolites like sugars found in cancer cells. This approach enables the precise identification and destruction of a wide range of tumors across various tissue types.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers evade detection by the immune system because they do not express traditional tumor-specific antigens recognized by T cells. This limits the effectiveness of conventional T-cell therapies that rely on these antigens to target and destroy cancer cells.
Solution
M-TCR is developing a novel class of T-cell therapies that target the MR1 molecule, an antigen-presenting molecule that displays metabolites derived from cancer cells. By engineering T cells to recognize MR1-metabolite complexes, M-TCR's approach enables the identification and destruction of a broad spectrum of cancers, regardless of tissue type or specific genetic mutations. This technology overcomes the limitations of traditional antigen-based T-cell therapies, offering a potential treatment for cancers that are currently difficult to target.
Target Audience
The primary target audience includes patients with cancers that are refractory to existing therapies, as well as oncologists and hematologists seeking novel treatment options for their patients.
Features
- T-cell receptor (TCR) engineering to target MR1-metabolite complexes on cancer cells
- Broad applicability across various cancer types and tissue origins
- Potential to overcome tumor heterogeneity and antigen escape mechanisms
- Preclinical validation demonstrating efficacy in diverse cancer models